Chelsea Counsel Company’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.59M | Sell |
5,255
-135
| -3% | -$73.3K | 1.15% | 25 |
|
|
2025
Q4 | $3.13M | Sell |
5,390
-20
| -0.4% | -$11.3K | 1.34% | 22 |
|
|
2025
Q3 | $2.63M | Sell |
5,410
-10
| -0.2% | -$4.66K | 1.17% | 25 |
|
|
2025
Q2 | $2.2M | Sell |
5,420
-1,740
| -24% | -$728K | 1.09% | 26 |
|
|
2025
Q1 | $3.57M | Sell |
7,160
-112
| -2% | -$60.7K | 1.94% | 14 |
|
|
2024
Q4 | $3.79M | Sell |
7,272
-490
| -6% | -$269K | 1.95% | 12 |
|
|
2024
Q3 | $4.8M | Sell |
7,762
-980
| -11% | -$580K | 2.37% | 12 |
|
|
2024
Q2 | $4.84M | Sell |
8,742
-8
| -0.1% | -$4.58K | 2.41% | 12 |
|
|
2024
Q1 | $5.09M | Sell |
8,750
-240
| -3% | -$135K | 2.89% | 11 |
|
|
2023
Q4 | $4.77M | Sell |
8,990
-220
| -2% | -$106K | 2.53% | 10 |
|
|
2023
Q3 | $4.66M | Sell |
9,210
-50
| -0.5% | -$26.6K | 2.4% | 10 |
|
|
2023
Q2 | $4.83M | Sell |
9,260
-150
| -2% | -$80.9K | 2.38% | 11 |
|
|
2023
Q1 | $5.43M | Sell |
9,410
-415
| -4% | -$234K | 2.64% | 11 |
|
|
2022
Q4 | $5.41M | Sell |
9,825
-1,683
| -15% | -$892K | 2.7% | 11 |
|
|
2022
Q3 | $5.84M | Sell |
11,508
-592
| -5% | -$331K | 3.6% | 9 |
|
|
2022
Q2 | $6.57M | Sell |
12,100
-500
| -4% | -$275K | 3.38% | 9 |
|
|
2022
Q1 | $7.44M | Sell |
12,600
-750
| -6% | -$431K | 3.28% | 9 |
|
|
2021
Q4 | $8.91M | Sell |
13,350
-480
| -3% | -$300K | 3.86% | 7 |
|
|
2021
Q3 | $7.9M | Buy |
13,830
+90
| +0.7% | +$49.4K | 3.59% | 6 |
|
|
2021
Q2 | $6.93M | Buy |
13,740
+20
| +0.1% | +$9.44K | 3.19% | 8 |
|
|
2021
Q1 | $6.26M | Sell |
13,720
-345
| -2% | -$165K | 3.1% | 8 |
|
|
2020
Q4 | $6.55M | Sell |
14,065
-2,573
| -15% | -$1.21M | 3.37% | 8 |
|
|
2020
Q3 | $7.35M | Sell |
16,638
-1,525
| -8% | -$630K | 4.34% | 4 |
|
|
2020
Q2 | $6.58M | Buy |
18,163
+46
| +0.3% | +$15.4K | 4.06% | 5 |
|
|
2020
Q1 | $5.14M | Sell |
18,117
-13,445
| -43% | -$4.24M | 4.03% | 7 |
|
|
2019
Q4 | $10.3M | Sell |
31,562
-2,677
| -8% | -$812K | 6.24% | 4 |
|
|
2019
Q3 | $9.97M | Sell |
34,239
-5,602
| -14% | -$1.6M | 6% | 3 |
|
|
2019
Q2 | $11.7M | Sell |
39,841
-215
| -0.5% | -$59.2K | 6.26% | 3 |
|
|
2019
Q1 | $11M | Sell |
40,056
-175
| -0.4% | -$43.6K | 5.91% | 3 |
|
|
2018
Q4 | $9M | Sell |
40,231
-92
| -0.2% | -$21.6K | 5.46% | 4 |
|
|
2018
Q3 | $9.84M | Buy |
40,323
+3,465
| +9% | +$797K | 5.13% | 5 |
|
|
2018
Q2 | $7.63M | Sell |
36,858
-3,698
| -9% | -$785K | 4.54% | 6 |
|
|
2018
Q1 | $8.37M | Sell |
40,556
-764
| -2% | -$160K | 5.38% | 5 |
|
|
2017
Q4 | $7.85M | Sell |
41,320
-5,370
| -12% | -$1.03M | 4.19% | 6 |
|
|
2017
Q3 | $8.83M | Sell |
46,690
-775
| -2% | -$140K | 4.42% | 6 |
|
|
2017
Q2 | $8.28M | Sell |
47,465
-1,900
| -4% | -$319K | 4.31% | 6 |
|
|
2017
Q1 | $7.58M | Sell |
49,365
-900
| -2% | -$138K | 3.9% | 6 |
|
|
2016
Q4 | $7.09M | Buy |
50,265
+235
| +0.5% | +$34.6K | 3.73% | 5 |
|
|
2016
Q3 | $7.96M | Buy |
50,030
+315
| +0.6% | +$48.5K | 4.07% | 5 |
|
|
2016
Q2 | $7.35M | Buy |
49,715
+202
| +0.4% | +$29.8K | 3.32% | 5 |
|
|
2016
Q1 | $7.01M | Buy |
49,513
+440
| +0.9% | +$59K | 2.26% | 12 |
|
|
2015
Q4 | $6.96M | Sell |
49,073
-4,110
| -8% | -$548K | 2.1% | 15 |
|
|
2015
Q3 | $6.5M | Sell |
53,183
-930
| -2% | -$121K | 1.55% | 23 |
|
|
2015
Q2 | $7.02M | Buy |
54,113
+1,975
| +4% | +$257K | 1.57% | 23 |
|
|
2015
Q1 | $7M | Buy |
52,138
+1,245
| +2% | +$160K | 1.51% | 23 |
|
|
2014
Q4 | $6.38M | Sell |
50,893
-710
| -1% | -$86.3K | 1.31% | 29 |
|
|
2014
Q3 | $6.28M | Buy |
51,603
+110
| +0.2% | +$13.4K | 1.25% | 30 |
|
|
2014
Q2 | $6.08M | Buy |
51,493
+1,320
| +3% | +$155K | 1.19% | 31 |
|
|
2014
Q1 | $6.03M | Buy |
50,173
+5,138
| +11% | +$611K | 1.23% | 32 |
|
|
2013
Q4 | $5.01M | Buy |
45,035
+1,290
| +3% | +$128K | 1.19% | 36 |
|
|
2013
Q3 | $4.03M | Buy |
43,745
+5,760
| +15% | +$521K | 0.84% | 42 |
|
|
2013
Q2 | $3.21M | Buy |
+37,985
| New | +$3.16M | 0.84% | 41 |
|
Other funds holding TMO
VCM
Chelsea Counsel Company's TMO Position: Q1 2026 in Review
Chelsea Counsel Company reduced its Thermo Fisher Scientific (TMO) stake by 2.5% in Q1 2026, selling an estimated $73.3K and leaving 5,255 shares worth $2.59M. The position accounts for 1.15% of the portfolio, ranked #25.
Chelsea Counsel Company first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.7M in Q2 2019. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Chelsea Counsel Company held 5,255 shares of Thermo Fisher Scientific worth $2.59M as of Q1 2026.
- Chelsea Counsel Company sold 135 Thermo Fisher Scientific shares in Q1 2026, an estimated $73.3K.
- Thermo Fisher Scientific made up 1.15% of Chelsea Counsel Company's portfolio in Q1 2026, its #25 holding.
- Chelsea Counsel Company first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
- Chelsea Counsel Company's Thermo Fisher Scientific position peaked at $11.7M in Q2 2019.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.